LPAR5 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL230076	0.42	10/20
SCHEMBL258032	1.00	7/20
SCHEMBL258094	1.00	7/20
SCHEMBL258118	1.00	7/20
SCHEMBL258136	1.00	7/20
SCHEMBL258161	1.00	7/20
SCHEMBL45056	0.97	6/20
SCHEMBL250888	0.97	6/20
SCHEMBL370759	0.67	6/20
SCHEMBL88391	0.49	6/20
SCHEMBL184782	0.45	6/20
SCHEMBL184279	0.43	6/20
SCHEMBL184503	0.40	6/20
SCHEMBL209403	0.33	6/20
SCHEMBL258036	0.74	5/20
SCHEMBL258048	0.74	5/20
SCHEMBL258056	0.74	5/20
SCHEMBL258058	0.74	5/20
SCHEMBL258063	0.74	5/20
SCHEMBL81078	0.63	5/20

Clinical trials — most relevant to LPAR5 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Indicated Prevention With Omega-3 Fatty Acids in Adolescents With 'At-Risk-Mental-State' for Psychosis	PHASE4	COMPLETED
Eicosapentaenoic Acid Cerebral Vasospasm Therapy Study	PHASE4	COMPLETED
Montelukast in Parkinson Disease	PHASE2/PHASE3	RECRUITING
Ramatroban/Montelukast Versus Montelukast/Placebo on the Early Allergic Reaction in Asthma Sensitive to House Dust Mite	PHASE2/PHASE3	WITHDRAWN
Combined Treatment of Methotrexate + Glucocorticoids Versus Glucocorticoids Alone in Patients With PM and DM	PHASE3	COMPLETED
A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin	PHASE2	UNKNOWN
GSK2190915 Neutrophilic Asthma Study	PHASE2	COMPLETED
GSK2190915A - Bioavailability Study	PHASE1	COMPLETED
A Repeat Dose Study to Investigate the Interaction of GSK2190915 on the Pharmacokinetics of Rosuvastatin	PHASE1	COMPLETED
Remote Ischaemic Conditioning in Endovascular Recanalization for Proximal Anterior Circulation Occlusion Study	PHASE1	UNKNOWN
Assessment of Coronary Plaque Composition	PHASE1	COMPLETED
PET Brain and Whole Body Distribution Studies for Nociceptin/Orphanin FQ Peptide (NOP) Receptor Using [11C]NOP-1A	EARLY_PHASE1	COMPLETED
Longitudinal Study on Bacterial Production of LPC and LPA in Patients With Inflammatory Bowel Disease	nan	RECRUITING
Effects of Ozanimod on Immune-mediated Mechanisms of Neurodegeneration in Multiple Sclerosis - a Preclinical Study	nan	UNKNOWN
Vulvodynia: Identification of Potential Relevant Biomarkers	nan	COMPLETED
Evaluation of Plasma Sphingosine-1-Phosphate as A Diagnostic and Prognostic Biomarkers of Community-Acquired Pneumonia	nan	UNKNOWN
Development of Therapeutic Approaches Modulating Molecular Targets Implicated on Cancer Stem Cell-related Aggressiveness	nan	UNKNOWN
Positron Emission Tomography (PET) to Study Brain Signaling	nan	COMPLETED
LDL-Apheresis for FSGS CardioRenal Outcomes	nan	COMPLETED
Dose-response Effect of Pine Nut Oil as a Dual FFA1 and FFA4 Agonist on Glucose Tolerance in Healthy Humans.	nan	COMPLETED
Physiopathology of Pulmonary Arterial Hypertension: Mechanistic Studies	nan	UNKNOWN
The Severe Asthma Research Program III-Boston Clinical Site	nan	COMPLETED
Investigating the Metabolic and Lipidomic Profiles That Are Associated With Varying Grades of Diabetic Maculopathy and Retinopathy in South Wales	nan	RECRUITING
Assessment of CXCL5 Level in SLE Patients and Its Correlation with Disease Activity	nan	NOT_YET_RECRUITING
Effect of Dietary Oils as G-protein-coupled Receptor Agonists on Glucose Tolerance	nan	UNKNOWN
In Vitro Demonstration of Direct Platelet-Related Effects of PCSK9 Enzyme	nan	NOT_YET_RECRUITING
FFAR Agonist on Incretins, Insulin, Lipids and Inflammation	nan	COMPLETED
Autotaxin (ATX) as a Marker for Breast Cancer	nan	UNKNOWN
Fish Oil and Nonalcoholic Fatty Liver Disease (NAFLD) Study	nan	COMPLETED
Effects of Probiotics on Gut Microbiota, Endocannabinoid and Immune Activation and Symptoms of Fatigue in Dancers	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a LPAR5 binder may also engage these)

Protein	Name	Similarity
Q3ZC80	—	1.000	Q3ZC80 →
Q149R9	—	0.998	Q149R9 →
Q920E0	—	0.993	Q920E0 →
P2RY11	P2Y purinoceptor 11	0.987	landscape →
O00270	—	0.981	O00270 →
F8VQN3	—	0.981	F8VQN3 →
O88634	—	0.980	O88634 →
RXFP4	Relaxin-3 receptor 2	0.978	landscape →
Q76JU9	—	0.976	Q76JU9 →
Q6NS65	—	0.976	Q6NS65 →
GPR17	Uracil nucleotide/cysteinyl leukotriene receptor	0.976	landscape →
OXER1	Oxoeicosanoid receptor 1	0.975	landscape →
Q09QM4	—	0.975	Q09QM4 →
P34997	—	0.974	P34997 →
NTSR2	Neurotensin receptor type 2	0.973	landscape →
F2RL3	Proteinase-activated receptor 4	0.973	landscape →
Q63384	—	0.973	Q63384 →
CXCR5	C-X-C chemokine receptor type 5	0.973	landscape →
A0A6I8PUB9	—	0.972	A0A6I8PUB9 →
GALR2	Galanin receptor type 2	0.971	landscape →
P70310	—	0.971	P70310 →
FFAR3	Free fatty acid receptor 3	0.971	landscape →
O09027	—	0.970	O09027 →
Q8K3T4	—	0.970	Q8K3T4 →
Q9Z2J6	—	0.970	Q9Z2J6 →
O08726	—	0.969	O08726 →
Q7TQP4	—	0.969	Q7TQP4 →
Q04683	—	0.969	Q04683 →
Q76JV1	—	0.968	Q76JV1 →
P43142	—	0.968	P43142 →